- Home
- QLYS vs TOVX Comparison
QLYS vs TOVX Comparison
Compare QLYS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLYS
- TOVX
- Stock Information
- Founded
- QLYS 1999
- TOVX 2001
- Country
- QLYS United States
- TOVX United States
- Employees
- QLYS N/A
- TOVX N/A
- Industry
- QLYS Computer Software: Prepackaged Software
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- QLYS Technology
- TOVX Health Care
- Exchange
- QLYS Nasdaq
- TOVX Nasdaq
- Market Cap
- QLYS 4.4B
- TOVX 3.8M
- IPO Year
- QLYS 2012
- TOVX 2006
- Fundamental
- Price
- QLYS $137.71
- TOVX $0.48
- Analyst Decision
- QLYS Hold
- TOVX Hold
- Analyst Count
- QLYS 17
- TOVX 1
- Target Price
- QLYS $137.36
- TOVX N/A
- AVG Volume (30 Days)
- QLYS 317.4K
- TOVX 172.2K
- Earning Date
- QLYS 08-05-2025
- TOVX 08-12-2025
- Dividend Yield
- QLYS N/A
- TOVX N/A
- EPS Growth
- QLYS 13.46
- TOVX N/A
- EPS
- QLYS 4.89
- TOVX N/A
- Revenue
- QLYS $621,665,000.00
- TOVX N/A
- Revenue This Year
- QLYS $9.64
- TOVX N/A
- Revenue Next Year
- QLYS $6.63
- TOVX N/A
- P/E Ratio
- QLYS $28.14
- TOVX N/A
- Revenue Growth
- QLYS 9.14
- TOVX N/A
- 52 Week Low
- QLYS $112.61
- TOVX $0.40
- 52 Week High
- QLYS $170.00
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- QLYS 44.93
- TOVX 49.42
- Support Level
- QLYS $134.06
- TOVX $0.42
- Resistance Level
- QLYS $151.10
- TOVX $0.48
- Average True Range (ATR)
- QLYS 3.46
- TOVX 0.03
- MACD
- QLYS -1.02
- TOVX 0.02
- Stochastic Oscillator
- QLYS 21.42
- TOVX 78.22
About QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.